ICP
NTLA icon

Interchange Capital Partners’s Intellia Therapeutics NTLA Stock Holding History

Interchange Capital Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.7K Buy
11,073
+77
+0.7% +$981 0.02% 278
2025
Q4 		$98.9K Sell
10,996
-699
-6% -$9.62K 0.02% 418
2025
Q3 		$202K Buy
11,695
+1,030
+10% +$12.7K 0.04% 350
2025
Q2 		$100K Sell
10,665
-1,202
-10% -$9.87K 0.02% 278
2025
Q1 		$84.4K Sell
11,867
-2,584
-18% -$26.1K 0.02% 268
2024
Q4 		$163K Sell
14,451
-5,833
-29% -$91K 0.06% 246
2024
Q3 		$417K Buy
20,284
+139
+0.7% +$3.21K 0.15% 162
2024
Q2 		$456K Buy
20,145
+9,236
+85% +$220K 0.17% 147
2024
Q1 		$303K Buy
10,909
+670
+7% +$18.6K 0.2% 121
2023
Q4 		$311K Buy
10,239
+605
+6% +$17.4K 0.23% 106
2023
Q3 		$305K Buy
9,634
+735
+8% +$28.5K 0.24% 102
2023
Q2 		$363K Sell
8,899
-3,129
-26% -$127K 0.28% 87
2023
Q1 		$448K Buy
+12,028
New +$472K 0.24% 103
2022
Q4 		– Sell
-7,890
Closed -$441K – 151
2022
Q3 		$441K Sell
7,890
-838
-10% -$52K 0.48% 56
2022
Q2 		$451K Sell
8,728
-70
-0.8% -$3.56K 0.51% 59
2022
Q1 		$639K Sell
8,798
-582
-6% -$49.3K 0.66% 38
2021
Q4 		$1.11M Buy
9,380
+1,189
+15% +$149K 1.11% 14
2021
Q3 		$1.1M Buy
8,191
+437
+6% +$66.2K 1.84% 15
2021
Q2 		$1.25M Sell
7,754
-18,577
-71% -$1.45M 1.94% 12
2021
Q1 		$2.19M Sell
26,331
-3,169
-11% -$213K 1.19% 9
2020
Q4 		$1.6M Buy
+29,500
New +$1.07M 0.87% 16

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Interchange Capital Partners's NTLA Position: Q1 2026 in Review

Interchange Capital Partners increased its Intellia Therapeutics (NTLA) stake by 0.7% in Q1 2026, buying an estimated $981 and bringing the position to 11,073 shares worth $78.7K. The position accounts for 0.02% of the portfolio, ranked #278.

Interchange Capital Partners first reported a position in NTLA in Q4 2020 and has held it in 21 quarters since. The position peaked at $2.19M in Q1 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Interchange Capital Partners held 11,073 shares of Intellia Therapeutics worth $78.7K as of Q1 2026.
  • Interchange Capital Partners bought 77 Intellia Therapeutics shares in Q1 2026, an estimated $981.
  • Intellia Therapeutics made up 0.02% of Interchange Capital Partners's portfolio in Q1 2026, its #278 holding.
  • Interchange Capital Partners first reported a position in Intellia Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Interchange Capital Partners's Intellia Therapeutics position peaked at $2.19M in Q1 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Interchange Capital Partners's 13F filing for Q1 2026, filed 24 Apr 2026.